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Abstract
Purpose: Identification of all common and potentially avoidable adverse events is crucial to further improve the
quality of medical care. The intention of the current study was to evaluate a standardized physician independent
survey format on adverse events in total knee arthroplasty. The protocol for reporting adverse drug events
following the International Conference of Harmonisation of technical requirements for registration of
pharmaceuticals for human use (ICH) was adopted for adverse events occurring during surgical interventions.
Material and methods: Data of a prospective sequential cohort trial introducing a clinical pathway for total knee
arthroplasty was analysed. Reporting of adverse events was done by a physician independent study nurse using
the modified ICH-Good Clinical Practice (GCP) format (Structure and Content of Clinical study reports - E3) in 260
patients. The adverse events were graded to their severity and their potential relation to surgical treatment.
Results: A total of 55 patients (21%) suffered from an adverse event and 16 (6%) from a serious adverse event. In
38 patients’ one adverse event occurred, 12 patients showed 2 adverse events and 5 patients suffered from a
combination of an adverse and a serious adverse event. A serious adverse event alone occurred in 11 patients. The
incidence of adverse events (Fisher p = 0.448) and serious adverse (p = 0.126) events showed no significant
difference between the two cohorts. The most common adverse events were deep vein thrombosis (8% and 5%)
followed by wound healing problems (1% and 0%) and haematoma (1% and 3%). A wide range of non surgical
adverse events were recorded with low incidence levels.
Conclusion: The use of the modified ICH-GCP format supports standardization of adverse event reporting. Routine
assessment of adverse events by a study nurse revealed higher incidence rates of adverse events in total knee
arthroplasty. We recommend the implementation of trained paramedical staff for the documentation of adverse
events in routine clinical care.
Introduction
Total knee replacement provides safe and effective treat-
ment for patients suffering from end stage osteoarthritis
[1]. Improvement in medical care offers total knee repla-
cement to an increasing number of older patients even
with severe comorbidities[2]. However, for the treatment
of older and sicker patients an increased rate of medical
complications has to be assumed,[3] but nevertheless
the reported rate of adverse events is low, however,
especially for the data reported to the national public
external quality assuring system in Germany[4]. The
reporting of adverse events in former papers on total
joint replacement mainly focuses on major surgical
adverse events like wound infection, fracture or loosen-
ing of the implant[5-10]. Therefore medical adverse
events are likely to be underreported in these investiga-
tions [11]. In an evidence report on total knee arthro-
plasty [12] a more complete list of adverse medical as
well as surgical events is published. Alfonso et al. [13]
reviewed the non surgical complications after total hip
and total knee arthroplasty and also used a more
detailed listing of adverse events.
Beside this tendency in the orthopaedic literature
there is an ongoing debate about the reliability of
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Identification of all common and potentially avoidable
adverse events is crucial to further improve the quality
of medical care. Routine reporting by physicians identi-
fied fewer events than medical record review[15]. There-
fore a different workflow to monitor adverse events in
surgical patients may be advisable. A possible entry into
an increased accuracy in monitoring may be the intro-
duction of a trained study nurse or medical documenta-
tion assistant into the clinical routine surveillance
system to thoroughly monitor adverse events in surgical
patients undergoing total knee replacement; the well-
established report instruction (Structure and Content of
clinical study reports - E3) of the Good Clinical Practice
(GCP) Guideline from the International Conference on
Harmonisation of technical requirements for registration
of pharmaceuticals for human use (ICH GCP[16] and
ICH E3) may provide an efficient and standardized
rationale for this additional stage in quality assessment.
Patients and Methods
The intention of the current study was to propose and
illustrate a standardized documentation and reporting
assessment tool for (serious) adverse event patterns in
Orthopaedic Surgery; furthermore the putative effect of
the implementation of a physician independent survey
on adverse events in total knee arthroplasty had to be
evaluated. For that purpose data of a prospective
sequential cohort trial introducing a clinical pathway for
total knee arthroplasty was re-analysed. Two sequential
cohorts were recruited with the aim of simultaneously
estimating the process costs from the health care provi-
ders’ perspective and the patient-related benefit of TKA.
A total of 260 patients with the clinical indication for
TKA were enrolled consecutively. Data on the present
state was collected with a process documentation of the
clinical course within a first cohort of 132 patients. The
recorded data was used to derive and then implement
an interdisciplinary clinical pathway on TKA; after a
three months period of confirming this pathway propo-
sal within clinical routine environments, a second inde-
pendent cohort of 128 patients undergoing TKA was
recruited and documented at the same hospital. Further
sociodemographic details of both study cohorts are
given in table 1. Furthermore all study patients were
invited for a three months recall. The underlying pro-
spective cohort design was ratified by the local Indepen-
dent Ethics Committee by June 25
th 2005. All patients
gave informed consent to take part in this trial.
Surgical procedure
The study population consisted of patients with primary
or secondary knee osteoarthritis grade 3 and 4 according
to Kellgren and Lawrence[17]. Surgery was performed in
nearly all patients under regional anaesthesia and a tour-
niquet was applied after admission of preoperative anti-
biotic prophylaxis (third generation cephalosporine).
Through a straight skin incision and a medial parapatel-
lar approach a cemented Natural Knee II (Fa. Zimmer,
Germany) total knee arthroplasty without resurfacing of
the patella was implanted. All patients undergoing total
knee replacement were graded to be at high risk for
deep venous thrombosis. All patients received Arixtra
1×1s .c .f o r6w e e k s .P o s t o p e r a t i v e l ya l lp a t i e n t sw e r e
allowed for immediate full weight bearing. After dis-
charge from the hospital the patients were transferred
to an inpatient rehabilitation unit for additional three
weeks.
Monitoring of adverse events and data collection
All data collection preoperatively and at follow-up was
done by a trained medical documentation assistant.
Functional ability and health-related quality of life were
assessed by means of appropriate instruments
(WOMAC[18], EQ-5D[19] and Knee Society Knee
Score)[20]. For monitoring of adverse and serious
adverse events the definitions of the ICH GCP were
adapted for surgical interventions and implemented as
described below. The original wording is given in square
brackets followed by the new text in italic letters.
Definition of adverse events (AE): any unexpected med-
ical occurrence in a patient or clinical investigation sub-
ject [administered a pharmaceutical product] undergoing
surgical treatment, which does not necessarily have a
causal relationship with this treatment. An adverse
event (AE) can therefore be any unfavourable and unin-
tended sign (including an abnormal laboratory finding),
symptom, or disease temporally associated with [the use
of a medicinal (investigational) product] surgical treat-
ment, whether or not related to [the medicinal (investi-
gational) product] surgical treatment.
definition of serious adverse events (SAE): any unex-
pected medical occurrence [at any dose] in the operative
period, which resulted in death, went life-threatening,
required inpatient hospitalization or prolongation of
existing hospitalization, or resulted in persistent or sig-
nificant disability/incapacity.
Averse events and serious adverse events were
recorded at time of clinical appearance or at time of
first available information to the Orthopaedic surgery
department. In any case of a suspected deep vein throm-
bosis the patients were admitted to the university vascu-
l a rc e n t r ea n df u r t h e rs o n o g r a p h i cd i a g n o s t i c sw e r e
carried out. There is no general screening for DVT in
patients undergoing TKA. A medical documentation
assistant interviewed all patients at follow up and
actively screened any adverse event possible after knee
arthroplasty. In order to grade the adverse events
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surgical treatment all (S)AE reports by the medical doc-
umentation assistant were reviewed by the coordinating
clinical investigator. Almost all patients suffering from
an adverse event were consulted by a specialist. The (S)
AE events were graded “surely, possibly, probably, non
related”. Only in the case of a undoubtedly pre-existing
disease like a Hyperhomocystinemia the (S)AE was
graded “non related”. In all other cases a possible rela-
tion to surgical treatment was considered. At the time
of the three months follow-up investigation the impact
of the adverse event on mid-term outcome after total
knee replacement was estimated. No structured inter-
views were done afterwards.
Statistical analysis
The descriptive analysis of this embedded quality inves-
tigation was based on two-sided Fisher tests at a local
5% significance level to compare the cumulative inci-
dences of adverse events and serious adverse events
between the two sequential cohorts. The observed
(serious) adverse events were listed according to the
ICH report form.
To further investigate possible factors contributing to
the observed (serious) adverse event patterns a severity
score on the individual adverse event patterns was consti-
tuted: The appearance of two adverse events or a combi-
nation of an adverse event together with a serious
adverse event was hypothesized to be a more severe
impairment on individual health than a single adverse
events or no adverse event at all. The severity score
counted one point for every adverse event and two points
for serious adverse events. Description of this score was
based on relative frequencies. Furthermore a multiple
logistic regression model was fitted for this score by
means of a forward selection model and Likelihood Ratio
tests at a local 5% significance level: A total score of 2
points or more was considered “severe” and applied as a
surrogate endpoint of the overall (S)AE patterns; age at
time of surgery, the patients’ individual comorbidity and
complexity level (pccl, derived form the DRG calculation),
gender, educational level, WOMAC index before surgery
and cut suture time were introduced into the model
as possible explaining factors, the patients’ respective
cohort - before versus after pathway implementation -
was furthermore included.
All numerical evaluations were based on the software
SPSS® (release 17.0 for Windows®).
Results
A total of 55 patients (21%) suffered from an adverse
event and 16 (6%) from a serious adverse event. The
improvement in terms of patient related outcome mea-
sures for WOMAC, EQ-5 D and Knee Society Knee and
Function Score is given in table 2. In 38 patients’ one
adverse event occurred, 12 patients showed 2 adverse
events and 5 patients suffered from a combination of an
adverse and a serious adverse event. A serious adverse
event alone occurred in 11 patients. In the entire cohort
at total of 68 adverse events and 16 serious adverse
events were recorded, 30 + 5 of which reported form
the first cohort (23% + 4%) and 37+11 from the second
cohort (29% + 11%) after clinical pathway implementa-
tion. The incidence of adverse events (Fisher p = 0.448)
and serious adverse (p = 0.126) events showed no signif-
icant difference between the two cohorts. The most
common adverse events were deep vein thrombosis with
an occurrence rate of 8% and 5% for the lower leg in
the respective cohorts. Further surgical adverse events
like wound healing problems (1% and 0%) and haema-
toma (1% and 3%) were observed less frequently. Falls
(2%) were only reported for the second cohort. Further
adverse events were reported at a lower level of inci-
dence (Table 3).
In cohort 1 (before pathway implementation), a total
of 10 patients (8%) showed a severity adverse event
score of 2 or more, in cohort 2 (after pathway imple-
mentation) a total of 17 patients (13%). The logistic
regression model could only identify the individual pccl
(LR p < 0.001) and the a patient’s cohort designation
(LR p = 0.036) as significantly associated with this end-
point; neither age at time of surgery (LR p = 0.062) nor
gender (LR p = 0.106) nor educational level (LR
p = 0.096) nor cut/suture time (LR p = 0.366) nor
Table 1 Distribution characteristics for sociodemographic cofactors assessed in 132 patients, who underwent total
knee arthroplasty (TKA) before implementation of a critical pathway on TKA, versus 128 patients, who underwent TKA
after path implementation
Before pathway implementation
(n = 132)
After pathway implementation
(n = 128)
Age: median and range [years] 68 (43 - 88) years 70 (46 - 85) years
Females 64% 56%
living alone 32% 28%
under employment 8% 9%
graduate 20% 17%
Kirschner et al. Patient Safety in Surgery 2010, 4:12
http://www.pssjournal.com/content/4/1/12
Page 3 of 7WOMAC (LR p = 0.344) before surgery were found sig-
nificantly associated with the occurrence of a severity
score of 2 points and more.
Discussion
Improvement in medical care extends the life expec-
tancy of our patients and secondary increases the need
for total joint replacement[21]. For surgical procedures
with a high volume the introduction of clinical pathways
was promoted[22]. The quality of medical care can be
improved through the use of clinical pathways
embedded within a quality management system by con-
tinuously measuring and evaluating process and out-
come indicators[23]. Especially for elder patients this
systematic and structured improvement process could
be beneficial and illustrates again the relevance of the
PDCA-cycle of Walter Deming. Therefore a vital part of
continuous quality assurance is the monitoring of
adverse events and to evaluate whether these were
avoidable[24]. University hospitals are more likely to
treat patients at higher age and with more complex
comorbidities. Therefore a higher rate for adverse events
has to be assumed in these institutions.
The rates for adverse events (21%) and serious adverse
events (6%) in our patients appear relatively high when
compared to the official data of the national external
quality assurance system in Germany[4]. In this nation
wide database for example the average incidence of gen-
eral medical complications was reported to be 2% with a
reference limit of 5%. Data published by Parvizi et al. [3]
with 21% minor complications and 5% major complica-
tion, however, match better to our observations. Similar
results were found by Frosch et al.[25]. Alfonso [13] pro-
vided an extensive review of the non orthopaedic litera-
ture and confirmed a broad range of non surgical adverse
events in patients undergoing total joint replacement.
The importance to use accepted definitions was high-
lighted by Bruce et al.[14]. Especially in the context of
suspected wound infection he found only little evidence
for systemic measurement and monitoring of surgical
wound. The strict definition for persisting wound drai-
nage by Parvizi [3] as any secretion from the wound 48
hours post surgery is easy to use. In case of postoperative
haematoma or suspected wound infection active treat-
ment with revision of the wound is recommended. Tim-
ing of the intervention is important for further prognosis
[ 2 6 ] .I fi nd o u b tar e v i s i o ns h o u l db eu n d e r t a k e n .T h e
clear and comprehensible definition makes it easier for
the patient to understand the situation and to agree to
further surgery. We carried out 4 revisions for suspected
early infection and one for haematoma.
Falls of patients occurring after surgical procedures
performed under regional anaesthesia are reported in
the literature[27]. We observed these only in the second
cohort of our patients. During pathway implementation
no changes concerning the use of regional anaesthesia
were made. In contrast the patients of the second cohort
were offered to attend further information about the
disease, the operation and the pain management with
regional anaesthesia thereafter. The increased rate of
documented falls may be attributable to closer monitor-
ing of our patients. Higher age as well as multiple
comorbidities are a documented risk factors for the
occurrence of adverse events[28,29]. We were able to
Table 2 Medians and quartiles for the total WOMAC osteoarthritis index, EQ-5 D [%, 100% = optimum rating] and
Knee Society Knee and Function Score before and three months after total knee arthroplasty (TKA)
Before pathway implementation
(n = 132)
After pathway implementation
(n = 128)
EQ-5D
preoperative [%] 45% (35 - 50%) 50% (31 - 50%)
postoperative [%] 75% (60 - 85%) 75% (60 - 80%)
WOMAC
preoperative [%] 41% (32 - 48%) 44% (36 - 52%)
postoperative [%] 83% (68 - 91%) 82% (70 - 91%)
Knee Society
Knee Score
preoperative [pt] 43 (29-54) 46 (37-56)
postoperative [pt] 87 (69-94) 85 (65-92)
Knee Society Function Score
preoperative [pt] 50 (40-60) 55 (45-60)
postoperative [pt] 60 (50-75) 65 (55-76)
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vated pccl level in our patients.
Treatment of patients suffering from severe Parkinson
disease with brain stimulators is a focus of the neurolo-
gical and neurosurgical department at our university
[30]. In the postoperative period these patients are clo-
sely monitored by these specialists. The reported adverse
events in these patients may be an effect of this inten-
sive care. None of these patients showed worsened men-
tal state at the time of discharge.
Table 3 Adverse event and serious adverse event counts, percentages given in brackets, for 132 patients, who
underwent total knee arthroplasty (TKA) before implementation of a critical pathway on TKA, versus 128 patients,
who underwent TKA after path implementation
Before pathway implementation After pathway implementation Total
adverse event n = 132 n = 128 n = 260
Generalised seizure due to local anaesthetic intoxication 0 (0) 1 (1) 1 (0)
DVT (lower leg) 10 (8) 6 (5) 16 (6)
DVT (knee) 4 (3) 2 (2) 6 (2)
DVT (thigh) 0 (0) 1 (1) 1 (0)
Haematoma 1 (1) 3 (2) 4 (2)
Wound healing problems 1 (1) 0 (0) 1 (0)
Stiff knee 0 (0) 1 (1) 1 (0)
Gastrointestinal bleeding 0 (0) 3 (2) 3 (1)
Dekubital ulcer 1 (1) 2 (2) 3 (1)
Postoperative cognitive disorder 1 (1) 0 (0) 1 (0)
Speech disturbance and Hyperkinesia in Parkinson disease 2 (2) 1 (1) 3 (1)
Postoperative hypertonia 1 (1) 3 (2) 4 (2)
Cardiac blocks 2 (2) 2 (2) 4 (2)
Diarrhoea 1 (1) 1 (1) 2 (1)
Obstipation 0 (0) 1 (1) 1 (0)
Erysipel 1 (1) 0 (0) 1 (0)
Exanthema 1 (1) 3 (2) 4 (2)
Otolaryngology consultation* 2 (2) 0 (0) 2 (1)
Dentist consultation* 1 (1) 0 (0) 1 (0)
Urinary tract infection 0 (0) 2 (2) 2 (1)
Urologic consultation* 1 (1) 2 (2) 3 (1)
Fall 0 (0) 2 (2) 2 (1)
Posterior collum lesion (myelon)* 0 (0) 1 (1) 1 (0)
Hyperhomocystinemia* 0 (0) 1 (1) 1 (0)
Total AE 30 (23) 38 (29) 68 (26)
serious adverse event
Death during study period, unrelated 1 (1) 1 (1) 2 (1)
Resuscitation (cardiological cause) 1 (1) 0 (0) 1 (0)
Pulmonary embolism 1 (1) 0 (0) 1 (0)
Revision for infection 1 (1) 3 (2) 4 (2)
Revision for haematoma 1 (1) 0 (0) 1 (0)
Closed mobilisation 0 (0) 3 (2) 3 (1)
Opticusneuropathia 0 (0) 1 (1) 1 (0)
Myocardial infarction 0 (0) 1 (1) 1 (0)
Central vein thrombosis eye 0 (0) 1 (1) 1 (0)
Subcutaneous infection belly (related to DVT prophylaxis) 0 (0) 1 (1) 1 (0)
Total SAE 5 (4) 11 (9) 16 (6)
* Adverse events unrelated to surgical treatment
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cusneuropathia as well as the thrombosis of the central
eye vein is unrelated to treatment to our understanding.
Major surgical adverse events like revisions for haema-
toma or suspected infection are similar in both cohorts.
Treatment for decreased motion after total knee arthro-
plasty was more aggressive in the second cohort as part
of the clinical pathway[31]. In consequence we observed
three closed manipulations only in the second cohort.
There was an increase in serious adverse events for
cohort II, but the difference in incidence rates were not
found significant at all.
There are some limitations of the current study. We
reported the incidence of adverse events for a clinical
trial by means of a rather small series of 260 patients
only. Larger numbers of patients could probably identify
more influencing factors like age for the occurrence of
adverse events and identify additional (S)AEs with smal-
ler incidences than being observable by means of the
recent sample size. As the investigation was performed
at a tertiary referral centre our cases might represent a
selected cohort with a higher percentage of elderly,
more extended use of anticoagulative drugs and higher
prevalence of comorbidities. Generalization of the above
quantitative results is therefore limited; however, bearing
the primary intention of proposing and illustrating a
standardized reporting system, the pilot investigation
ended with a positive conclusion in confirming the feasi-
bility of the proposal demonstrated here.
In summary, further improvement in the quality of
medical care depends on full recognition of adverse
events. Routine assessment of adverse events by a
trained medical documentation assistant or study nurse
could lead to a more complete documentation and
therefore to a higher rate of reported adverse and ser-
ious adverse events. The independency of study nurse
assessment from physicians and the nursing team seem
to be useful to achieve a more constructive discussion
culture as highlighted by de Vries[32]. We therefore
recommend the implementation of trained paramedical
staff for the documentation of adverse events in routine
clinical care.
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